NCT00536692
Completed
Phase 2
Phase 2 Study of the Safety and Bioactivity of Topical Ocular Mecamylamine for the Treatment of Diabetic Macular Edema (DME)
CoMentis3 sites in 1 countrySeptember 2007
ConditionsDiabetic Macular Edema
Drugsmecamylamine
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Diabetic Macular Edema
- Sponsor
- CoMentis
- Locations
- 3
- Status
- Completed
- Last Updated
- 18 years ago
Overview
Brief Summary
This is an open-label study evaluating the safety and tolerability of topical ocular mecamylamine given twice a day in patients with diabetic macular edema (DME). Patients will be treated for 12 weeks.
Investigators
Eligibility Criteria
Inclusion Criteria
- •macular edema due to diabetic retinopathy
Exclusion Criteria
- •vision loss from other ocular disease
- •intraocular surgery within 3 months
- •intraocular anti-VEGF or steroids within 3 months
- •HbA1c \>12
Outcomes
Primary Outcomes
Not specified
Study Sites (3)
Loading locations...
Similar Trials
Terminated
Phase 1
Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVOWet Age-related Macular DegenerationRetinal Vein OcclusionDiabetic Macular EdemaNCT03790852Kodiak Sciences Inc121
Completed
Phase 2
RMP-A03 Ocular Suspension in Patients With PterygiumPterygiumNCT05794204Suzhou Raymon Pharmaceuticals Company, Ltd.77
Completed
Phase 2
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)Neovascular Age Related Macular DegenerationNCT01678963Ohr Pharmaceutical Inc.142
Recruiting
Phase 2
Volrustomig Priming Regimens Exploratory Phase II Platform StudyNon-small Cell Lung CancerNCT06448754AstraZeneca180
Completed
Phase 1
First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)Wet Age-related Macular DegenerationNCT04747197EyePoint Pharmaceuticals, Inc.17